focus -WSS

focus

author：comprehensive 2025-10-04 11:35:53 - browse：3665

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： A Q&A with Aletha Maybank, AMA’s chief health equity officer

focus

WSS

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Morphosys mixed study results for blood cancer drug

Why getting cancer drugs just got harder for rural patients

NYU radiologists take on the challenge of expensive MRI machines

FDA does about

Poor hospice wound care hurts patients and families

knowledge

focus

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Biotech companies concerned about China biosecurity crackdown

Activists slam private health insurers over coverage restrictions

Obesity now affects over 1 billion people worldwide, study finds

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Pfizer highlights cancer drugs it thinks could reignite investor interest

The high cost of giving birth even with insurance

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Moonlake's readout produced a cash windfall. Risks remain

World's first CRISPR

Wikipedia

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Anthos stroke drug appears safer than common blood thinner

Ransomware attacks on hospitals: Study outlines patient impact

Weight loss drug costs may need more research, senator suggests

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Congress must reauthorize a committee to support older Americans

focus

entertainment

entertainment

focus